EUCTR2014-003880-38-GB进行中（未招募）1 期
A Phase 1/2, Dose-Escalation Safety, Tolerability and Efficacy Study of BMN 270, an Adenovirus-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Patients with Severe Haemophilia A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Males that are 18 years or older with established severe haemophilia A as evidenced by their medical history. Patients will be considered as severe if their base FVIII level is 1 IU/dL or less
- •2. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days (EDs)
- •3. Greater or equal to 12 bleeding episodes only if receiving on-demand therapy over the previous 12 months. Does not apply to patients on prophylaxis
- •4. Able to sign informed consent and comply with requirements of the trial
- •5. No history of inhibitor, and results from a modified Nijmegen Bethesda assay of less than 0.6 Bethesda Units (BU) on 2 consecutive occasions at least one week apart within the past 12 months
- •6. Sexually active patients must be willing to use an acceptable method of contraception such as double barrier, including hormonal contraception for at least 6 months post-treatment. After 6 months, subjects may stop contraception use only if they have had 3 consecutive semen samples below the limit of detection of the test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction inhibition or AAV5 total antibodies
- •2. Any evidence of active infection or any immunosuppressive disorder.
- •3. HIV positive
- •4. Significant liver dysfunction as defined by abnormal elevation of: ALT (alanine transaminase) to 3 times the upper limit of normal; Bilirubin above 3 times the upper limit of normal; Alkaline phosphatase above 3 times the upper limit of normal; or INR (international normalized ratio) = 1.4.
- •5. Potential participants who have had a liver biopsy in the past 3 years are excluded if they had significant fibrosis of 3 or 4 as rated on a scale of 0-4
- •6. Evidence of any bleeding disorder not related to Haemophilia A
- •7. Platelet count of < 100 x 10^9/L
- •8. Creatinine = 1.5 mg/dL
- •9. Liver cirrhosis of any etiology as assessed by liver ultrasound
- •10. Hepatitis B if surface antigen is positive
- •11. Hepatitis C if RNA is positive
- •12. Treatment with any IP within 30 days prior to the end of the screening period
- •13. Any disease or condition at the physician’s discretion that would prevent the patient from fully complying with the requirements of the study including possible corticosteroid treatment outlined in the protocol. The physician may exclude patients unwilling or unable to agree on not using alcohol for the 16-week period following the viral infusion.
- •14. Prior treatment with any vector or gene transfer agent
- •15. Major surgery planned in the 16-week period following the viral infusion
- •16. Use of systemic immunosuppressive agents or live vaccines within 30 days before the viral infusion
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II safety and tolerability dose escalation study following the autologous infusion of expanded adult haematopoietic stem cells to patients with established myocardial ischaemia.EUCTR2006-000280-28-GBImperial College London40
进行中（未招募）
1 期
A phase I/II safety and tolerability dose escalation study following the autologous infusion of expanded adult haemopoietic stem cells to patients with liver insufficiency - Dose escalation autologous stem cell studyChronic liver insufficiencyMedDRA version: 9.1 Level: LLT Classification code 10024667 Term: Liver cirrhosisMedDRA version: 9.1 Level: LLT Classification code 10024670 Term: Liver disorderEUCTR2005-001222-83-GBImperial College London5
进行中（未招募）
1 期
A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan-N-sulfatase (rhHNS) Intrathecal Administration via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)EUCTR2009-015984-15-GBShire Human Genetic Therapies, Inc. (Shire HGT)12
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)Advanced MalignanciesMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-002831-14-DKIncyte Corporation325
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsEUCTR2016-002079-93-GBIncyte Biosciences International Sàrl163